Astria Therapeutics, Inc. - ATXS STOCK NEWS

Astria Therapeutics (NASDAQ:ATXS) announced its CEO, Jill C. Milne, will engage in a virtual fireside chat at the 1st Annual Hereditary Angioedema Conference on July 20 at 12:30 PM ET. The conference focuses on hereditary angioedema, a rare condition for which Astria is developing STAR-0215, a monoclonal antibody aimed at treating this disease. A live webcast will be available at this link, and an archived replay will be accessible on Astria's website for 30 days afterwards.

Astria Therapeutics (NASDAQ: ATXS) presented new preclinical data showing that STAR-0215 effectively inhibits plasma kallikrein in cynomolgus monkeys, supporting potential dosing once every three months. This was discussed at the European Academy of Allergy and Immunology 2022 Congress in Prague. The study demonstrated rapid inhibition and prolonged pharmacological activity, with expectations to begin a Phase 1a clinical trial in healthy volunteers this year. The goal is to develop a patient-friendly treatment for hereditary angioedema (HAE).

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), to be presented at the EAACI 2022 Hybrid Congress from July 1-3 in Prague. Pradeep Bista, VP of Discovery and Translational Sciences, will present findings on July 3 at 11:15 am CEST. STAR-0215 is designed for long-acting attack prevention, with dosing every three months or longer. The company plans to file an Investigational New Drug Application mid-year and initiate a Phase 1a trial with results expected by year-end.

Astria Therapeutics, Inc. (NASDAQ:ATXS) will present an overview of its lead program, STAR-0215, at the Jefferies Healthcare Conference on June 10 at 10:30 AM ET in New York. STAR-0215 is a monoclonal antibody aimed at treating hereditary angioedema, a rare immunological condition. The presentation will be led by CEO Jill C. Milne, Ph.D., and a webcast link is provided for access. An archived replay will be available on the company’s investor website for 30 days post-event.

Astria Therapeutics, Inc. (NASDAQ:ATXS) granted stock options for 5,500 shares as part of its 2022 Inducement Stock Incentive Plan on June 1, 2022. The options, aimed at new employees, have an exercise price of $3.12, equal to the stock's closing price on the grant date. Vesting occurs over four years, with 25% vesting on the first anniversary of each employee's start date and the rest monthly thereafter. This incentive plan conforms to Nasdaq Listing Rule 5635(c)(4) and is intended to attract talent in the biopharmaceutical sector focused on rare diseases.

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its quarterly financial results for Q1 2022 and shared updates on the STAR-0215 program for hereditary angioedema (HAE). The company plans to file an Investigational New Drug (IND) application mid-year 2022, aiming to begin a Phase 1a clinical trial shortly afterward, with initial results anticipated by year-end. Financially, Astria reported a net loss of $15.3 million, a significant improvement from $170.1 million in the same quarter last year. They maintain a cash position of $112.8 million to support operations into 2023.

Astria Therapeutics (NASDAQ: ATXS) has announced it will present new preclinical data on its drug STAR-0215, aimed at treating hereditary angioedema (HAE), at the Fc Receptor and IgG Targeted Therapies Conference in Boston, Massachusetts, from April 26-28, 2022. Jou-Ku Chung, the Head of Clinical Pharmacology, will present on April 27 at 3:00 PM ET. STAR-0215 is designed as a long-acting monoclonal antibody with the potential for quarterly dosing, with plans to file an Investigational New Drug application mid-2022 and commence a Phase 1a trial thereafter.

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced on April 1, 2022, the grant of equity awards under its 2022 Inducement Stock Incentive Plan. The awards, totaling options for 32,500 shares of common stock, were given to new employees as an incentive. Each option has an exercise price of $6.48, matching the closing stock price on the grant date. The options will vest over four years, contingent upon the employees' continued employment. Astria focuses on developing therapies for rare allergic and immunological diseases, with its lead program being STAR-0215 for hereditary angioedema.

Astria Therapeutics, Inc. (NASDAQ:ATXS) reported its financial results for Q4 and full year 2021, alongside updates on its STAR-0215 therapy for hereditary angioedema (HAE). The company plans to file an IND application for STAR-0215 mid-year and initiate a Phase 1a clinical trial with initial results expected by year-end. As of December 31, 2021, cash and equivalents totaled $125.5 million. The net loss for 2021 was $194.9 million, significantly impacted by a $164.6 million in-process R&D expense from acquiring Quellis Biosciences.